Foscarnet used in salvage therapy of HIV-1 patients harbouring multiple nucleotide excision mutations.

Abstract

We used foscarnet as induction therapy or as maintenance therapy in different dosing regimens in seven severely immunocompromised multidrug-resistant HIV-1 patients. During induction the median decrease in viral load was 1.8 log and increases in CD4 cell counts ranging from zero to 136 cells/mm 3 were observed during maintenance therapy, suggesting that foscarnet could be an option in salvage therapy in patients with no treatment options left.